logo
White House physician's verdict on Trump's health after chronic venous insufficiency diagnosis: ‘Abundance of caution'

White House physician's verdict on Trump's health after chronic venous insufficiency diagnosis: ‘Abundance of caution'

Mint18-07-2025
US President Donald Trump has been diagnosed with chronic venous insufficiency following complaints of leg swelling, but White House doctors stated Thursday that he remains in 'excellent health.'
The White House Medical Unit conducted a 'comprehensive examination' of Trump, 79, after recent photos showed him with swollen ankles and a bruised hand, White House Press Secretary Karoline Leavitt said at a press briefing, as reported by Bloomberg.
The ankle swelling is related to the disease, which occurs when damaged valves inside the veins struggle to keep blood flowing from the legs back to the heart. Leavitt called it a 'common condition, particularly in individuals over the age of 70.' The disorder affects about one in 20 adults, according to the Cleveland Clinic.
According to a report by Bloomberg, a subsequent memo from White House physician Sean Barbabella said doctors found 'no evidence of deep vein thrombosis (DVT) or arterial disease' and that 'no signs of heart failure, renal impairment, or systemic illness were identified.'
'President Trump remains in excellent health,' Barbabella wrote.
Leavitt said Trump is experiencing 'no discomfort' related to his ankles and the president underwent the exam 'out of an abundance of caution' after noting the lower leg swelling. The exam included vascular studies, an echocardiogram and ultrasounds. Blood testing produced results 'within normal limits,' she added.
The hand bruising is 'consistent with minor soft tissue irritation from frequent hand-shaking' and is also 'a well-known and benign side effect of aspirin therapy,' Leavitt said. Trump is taking the medicine as part of a 'standard cardiovascular prevention regimen,' she said.
In January, Trump became the oldest individual ever sworn in as U.S. president, exceeding his predecessor Joe Biden.
Throughout the 2024 election, Trump frequently criticised the now 82-year-old Biden for his age and physical endurance. However, Trump ultimately exited the race following a disastrous debate performance that intensified concerns about his own fitness.
Meanwhile, images showing swelling in Trump's hands and ankles raised further questions about his personal health. The left foot and swollen ankle of President Donald Trump are pictured as he sits with Bahrain's Crown Prince Salman bin Hamad Al Khalifa in the Oval Office of the White House, Wednesday, July 16, 2025, in Washington. (AP Photo/Alex Brandon)
Photos taken last weekend at the FIFA Club World Cup showed Trump's ankles appearing swollen inside his socks. Then on Tuesday, reporters noticed what seemed to be makeup covering marks on the president's hand as he left the White House for a trip to Pennsylvania.
(With inputs from Bloomberg)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cipla sees weight-loss drugs as the biggest opportunity in the Indian market
Cipla sees weight-loss drugs as the biggest opportunity in the Indian market

Mint

time4 hours ago

  • Mint

Cipla sees weight-loss drugs as the biggest opportunity in the Indian market

Drugmaker Cipla Ltd anticipates GLP-1 drugs, used for treating type-2 diabetes and obesity, to be a definite new therapy in the Indian market, and is exploring a wider foray, said chief executive Umang Vohra. 'The Indian market is particularly important to us, where we're looking at the whole GLP-1 category and not just Semaglutide alone,' Vohra told reporters in a media interaction on Friday after the company declared its June-quarter results. Semaglutide, a GLP-1 (glucagon-like peptide-1) drug sold under the brand name Wegovy in India by Novo Nordisk, goes off patent in March 2026. 'Our overall thinking is this is going to be pretty definitive in terms of a new therapy, in terms of a new section of the market and an opportunity that will be probably the biggest that we've seen in the last five years,' said Vohra. 'We're trying to evolve a strategy on what would make the most economic sense for us in this category.' The company also plans to launch Semaglutide in other markets where it goes off patent, although Vohra declined to name specific markets. Cipla will file to commercialize the product with partners as well as on its own, in what Vohra called a 'combination strategy'. 'We're going to be perhaps making two filings in some of the markets that are of importance across the world,' he said. The patent for Semaglutide is expiring in countries such as India, Canada, and Brazil in 2026. Cipla's first-quarter profit after tax (PAT) beat estimates, while its revenue was a miss. The company reported a PAT of ₹ 1,298 crore, up 10% year-on-year, against ₹ 1,198.5 crore, estimated by a Bloomberg poll of 22 brokerages. At ₹ 6,957 crore, its consolidated revenue increased 4% on-year but missed Bloomberg estimates of ₹ 7,057 crore. The company reported an Ebitda of ₹ 1,778 crore, up 4% on-year, with its Ebitda margin remaining steady on-year at 25.6%. Ebitda stands for earnings before interest, taxes, depreciation, and amortization. 'Underlying this performance has been the numbers from the One India business, which grew overall at 6% and within that, we've seen a higher growth from our [trade] generics and consumer healthcare business,' said Vohra, adding that branded prescription growth was lower on account of a muted season for acute therapies. The company reported $226 million in revenue from its North America business during the quarter, a drop of 9.6% from the previous year's revenue of $250 million. The North American business accounts for 28% of Cipla's revenues. 'This is in the range that we had guided at the beginning of this quarter…We've had two new launches, and our launch momentum hopes to continue as the rest of the year pans out,' Vohra said. While uncertainty over tariffs and regulatory shifts in the US continues, Vohra said Cipla's business is already significantly derisked. 'Fortunately or unfortunately, because of our facility issues that we've had in the last three years, due to citations at our sites, we had already started de-risking our business. And we built new facilities in the US,' he said. Vohra said while the firm expects some impact from US policy changes, it won't be a debilitating effect that will 'derail the way we've thought about our business'. Cipla also faces price erosion on blood cancer drug Revlimid and Lanreotide, used to treat neuroendocrine tumours, in the US this year. However, Vohra believes that the company has a product pipeline that will continue to drive growth over the next three to five years. Cipla's share price closed at ₹ 1,535.00 on Friday on National Stock Exchange, up 3.17%.

Hidden $1000 fee at your doctor's office? Here's the sneaky charge Americans just found out about
Hidden $1000 fee at your doctor's office? Here's the sneaky charge Americans just found out about

Time of India

time7 hours ago

  • Time of India

Hidden $1000 fee at your doctor's office? Here's the sneaky charge Americans just found out about

Americans have their heads out of the sand as they discover a strange extra fee on their doctor bills. Many people in the U.S. have found surprise charges after simple visits to the doctor. These charges are called 'facility fees' or 'outpatient hospital services.' They are often not explained clearly and can cost from hundreds to even $1,000 depending on the type of visit, as per the NBC News. A family in Minnesota was shocked by a $423 charge. They visited their doctor for their daughter's stomach pain. The 15-minute visit cost $201, but a separate fee of $423 was added for 'outpatient hospital services.' Another man in Ohio paid $645 in extra charges. He visited an ear, nose, and throat specialist and got charged $645 as a 'facility fee', as per the The Wall Street Journal. Explore courses from Top Institutes in Please select course: Select a Course Category Operations Management MBA Project Management Others Product Management CXO Data Science Cybersecurity Design Thinking Public Policy Technology healthcare MCA Finance Management others Leadership Digital Marketing Data Science Healthcare Artificial Intelligence Data Analytics PGDM Degree Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details ALSO READ: Intel to axe 24,000 jobs — is your state or country on the layoff list? Here's who's affected most by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo One patient paid as much as $1,000 just in added fees. This happened during a urology appointment, which already had its own doctor fee. Cleveland Clinic in Florida is also under fire for charging these fees. Patients were charged $95 to $174 just in facility fees for basic visits like family medicine or a specialist consultation, as per The Sun report. Many patients feel shocked and confused One patient, Brandy Macaluso-Owens, said the charge made her heart drop. She visited a gastroenterologist in Port St. Lucie, Florida, for 15 minutes and later received a $174 bill from Cleveland Clinic. Cleveland Clinic responded by saying that the fees are legal and necessary. They said these charges follow government rules and help fund outpatient clinics and 24/7 emergency care, as per the report by NBC News. Live Events These types of fees are becoming more common in the U.S. Hospitals are hiring more doctors, and some insurance plans now make patients pay more upfront before full coverage starts. There are no laws controlling how high these fees can be. Christine Monahan from Georgetown University said most states don't have limits, so hospitals can charge whatever amount they want. Who should pay these extra fees? Hospitals and insurance companies are fighting over who should pay. The American Hospital Association says insurance should cover it. But insurance companies argue these fees don't add any real value to care. What should you do if you can't afford the charge? Patricia Kelmar from the US Public Interest Research Group says to call your doctor's office — sometimes they remove the fee. If not, call your insurance company for help or discounts, as stated by NBC News report. ALSO READ: Jazz world mourns: Chuck Mangione dies at 84 — here's what we know about his final days Surprise fees aren't only in hospitals — restaurants have them too. A breakfast chain had added a 50-cent fee to a menu item, then removed it after complaints. Other restaurants are adding things like 'living wage' fees of 18%, causing some customers to boycott, according to the reports. FAQs Q1. What is a facility fee on a doctor bill? A facility fee is an extra charge some hospitals add for using their clinic space during a doctor visit, even if the visit is short. Q2. Why are patients being charged $1,000 or more after doctor visits? Some hospitals add high 'outpatient' or 'facility' fees, which are not regulated and can vary based on the location or type of care.

Centene Earnings Fall Short of Expectations as Woes Mount
Centene Earnings Fall Short of Expectations as Woes Mount

Mint

time8 hours ago

  • Mint

Centene Earnings Fall Short of Expectations as Woes Mount

(Bloomberg) -- Centene Corp. reported a surprise quarterly loss Friday, yet another disappointment for the embattled health insurer, which recently pulled its 2025 guidance citing revenue pressure. Shares dropped 11% before markets opened in New York. They had fallen 56% since the start of the year. Centene said it would provide updated guidance on a conference call with analysts, which starts at 8 a.m. New York time. The insurer chalked up the second-quarter loss to a miscalculation in its Affordable Care Act business — the same reason it pulled guidance earlier this year. Insurers receive compensation for taking on sicker patients in that program and Centene said it would receive less of that money than it had previously expected. For the second quarter, Centene announced an adjusted loss per share of 16 cents. Wall Street analysts expected a profit of 55 cents per share. 'We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory,' Sarah London, chief executive officer of Centene, said in the company's earnings statement. In the second quarter, the company spent 93% of premium revenues of medical costs, higher than the average analyst expectation of 91.6%. Investors prefer a lower number. The company said its health benefits ratio, the percentage of premium revenues spent on medical costs, rose from last year, largely because of the ACA revenue issue. Centene said it also saw higher medical costs in ACA plans, as well as increased costs in Medicaid, which mostly came from behavioral health, home health, and expensive drugs. --With assistance from John Tozzi. (Updates with new information throughout.) More stories like this are available on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store